Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:2012:849373.
doi: 10.1155/2012/849373. Epub 2012 Aug 27.

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

F Bellanti  1 , G Vendemiale, E Altomare, G Serviddio
Affiliations
Review

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C

F Bellanti et al. Clin Dev Immunol. 2012.

Abstract

Host genetic factors may predict the outcome and treatment response in hepatitis C virus (HCV) infection. Very recently, three landmark genome-wide association studies identified single nucleotide polymorphisms near the interleukin 28B (IL28B) region which were more frequent in responders to treatment. IL28B encodes interferon (IFN)λ3, a type III IFN involved in host antiviral immunity. Favourable variants of the two most widely studied IL28B polymorphisms, rs12979860 and rs8099917, are strong pretreatment predictors of early viral clearance and sustained viral response in patients with genotype 1 HCV infection. Further investigations have implicated IL28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL28B may be a key factor involved in host immunity against HCV. This paper presents an overview about the biological activity and clinical applications of IL28B, summarizing the available data on its impact on HCV infection. Moreover, the potential usefulness of IFNλ in the treatment and natural history of this disease is also discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Types I, II, and III IFN receptors and their downstream signalling pathways.
See this image and copyright information in PMC

References

    1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection. 2011;17(2):107–115. - PubMed
    1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases. 2005;5(9):558–567. - PubMed
    1. Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. European Journal of Clinical Investigation. 2010;40(10):950–959. - PubMed
    1. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C—natural history and cofactors. Alimentary Pharmacology and Therapeutics. 2005;22(supplement 2):74–78. - PubMed
    1. Manns MP, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C. Indian Journal of Gastroenterology. 2001;20(supplement 1):C47–C51. - PubMed

Publication types